CNBC July 23, 2024
Annika Kim Constantino, Ashley Capoot

Good afternoon! The first round of the Biden administration’s Medicare drug price negotiations is nearly finished, with two major deadlines approaching.

President Joe Biden’s signature Inflation Reduction Act gave Medicare the power to directly hash out drug prices with manufacturers for the first time in the federal program’s nearly six-decade history. That process aims to make expensive medications more affordable for older Americans, but the pharmaceutical industry argues that it is a threat to their revenue, profits and drug innovation.

The government and manufacturers have been in talks since February, when Medicare sent its initial price offer for each of the 10 medications selected almost a year ago. That includes diabetes treatments from Merck, AstraZeneca and Boehringer Ingelheim...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Medicare’s cobra effect: How a well-intentioned policy spiraled into a health care crisis
Interpreting The First Round Of Maximum Fair Prices Negotiated By Medicare For Drugs
US Will Still Pay At Least Twice as Much After Negotiating Drug Prices
How A Future Harris Administration Could Expand Medicare Drug Pricing Provisions
The Impact of the Proposed 2025 Physician Fee Schedule on Parity and Delivery

Share This Article